Compare PRIM & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRIM | KYMR |
|---|---|---|
| Founded | 1960 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.6B |
| IPO Year | N/A | N/A |
| Metric | PRIM | KYMR |
|---|---|---|
| Price | $166.01 | $84.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 24 |
| Target Price | ★ $143.73 | $105.96 |
| AVG Volume (30 Days) | 653.9K | ★ 776.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.64 | $18.36 |
| Revenue Next Year | $6.78 | N/A |
| P/E Ratio | $32.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.10 | $19.45 |
| 52 Week High | $174.43 | $103.00 |
| Indicator | PRIM | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 64.27 | 65.48 |
| Support Level | $161.12 | $80.36 |
| Resistance Level | $174.43 | $86.18 |
| Average True Range (ATR) | 8.49 | 4.07 |
| MACD | 0.49 | 1.09 |
| Stochastic Oscillator | 75.15 | 81.90 |
Primoris Services Corp is a provider of infrastructure services operating mainly in the United States and Canada. It provides a wide range of construction services, maintenance, replacement, fabrication and engineering services to a diversified base of customers. The reportable segments are the Utilities segment and the Energy segment. The Utilities segment operates in a range of services, including the installation and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communication systems. The Energy segment operates in a range of services that include engineering, procurement, and construction, retrofits, highway and bridge construction, demolition, site work, outages, pipeline construction and maintenance, and others.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.